BioMarin Pharmaceutical
Nasdaq BMRN · Novato, CA
Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Metabolic & endocrine · Musculoskeletal · Neurology · Renal & urogenital · Respiratory · Women's health
BioMarin Pharmaceutical is a clinical trial sponsor based in Novato, CA, listed as Nasdaq BMRN. It has 26 active clinical trials with 2,848 planned participants, across 12 therapeutic areas. Since 2021 it has completed 29 trials and stopped 5 early. Its FDA record on file shows 1 inspection.
Trial track record · since 2021
FDA record
Recent FDA actions
Financials · Nasdaq BMRN
Pipeline · 26 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
8 approved drug applications with a product on the market.
Questions about BioMarin Pharmaceutical
No warning letter naming BioMarin Pharmaceutical is on file. FDA has published 1 inspection classification naming it.
FDA has posted 1 inspection classification naming BioMarin Pharmaceutical. The latest inspection ended on 2026-06-09 and was classified VAI (voluntary action indicated). FDA posts a classification after its review, often months after the inspection ended.
BioMarin Pharmaceutical is lead sponsor of 26 active clinical trials on ClinicalTrials.gov, with 2,848 planned participants, in Cardiovascular, Dermatology, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 29 trials and stopped 5 early.
BioMarin Pharmaceutical is based in Novato, CA and is listed as Nasdaq BMRN. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with BioMarin Pharmaceutical; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-01.
The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.
Approve Suite is not affiliated with BioMarin Pharmaceutical. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.